It has been reported that HSP co-inducers, such as Bimoclomol, Geranylgeranylacetone (GGA), and celastrol, have a beneficial effect in the treatment of various inflammatory diseases by boosting HSP expression in experimental animal models, such as cerebrovascular disorders (ErdÖ and ErdÖ 1998), neurodegenerative diseases (Chow and Brown 2007), and uveitis (Kitamei et al. 2007). This evidence concerns the gene HSP90B2P and uveitis.